BridgeBio Oncology Therapeutics, Inc. (BBOT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$52.8M
Cash & Equivalents
$35.9M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$666M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06343402 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | PHASE1 | Recruiting | 350 |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | PHASE1 | Recruiting | 665 |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | PHASE1 | Recruiting | 392 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.